Abstract
Treatment of hypertension is the subject of endless professional discussions. The current situation reflect and approved the recommended treatments (together with the economic aspects of treatment are detailed discussed in the following websites: British company NICE - www.nice.org.uk) or newly registered drugs.
Let us mention for example, a new beta- blocker nebivolol, a renin inhibitor aliskiren, endothelin receptor antagonist bosentan or ambrisentan. In the following, we will focus especially the importance of receptor antagonists AT1 angiotensin II (ARBs).